BioNTech Financial News

Investing.com — U.S. futures retreated slightly Wednesday, with investors wary ahead of the latest Federal Reserve monetary policy decision.

The S&P 500 has demonstrated a robust rally in 2023 and the true champions emerged in the form of Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Meta (NASDAQ:META), Microsoft (NASDAQ:MSFT), Nvidia (NASDAQ:NVDA) and Tesla (NASDAQ:TSLA), propelling the index to new heights through their significant surges.

Pfizer on Wednesday forecast 2024 sales that were as much as $5 billion below Wall Street expectations due mostly to declining demand for COVID vaccines and treatment, driving shares down seven per cent in premarket trading.

We don’t support this browser anymore. This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Investing.com — U.S. futures edged higher Monday, as investors awaited the release of more quarterly corporate earnings as the new week starts with a positive tone.

FRANKFURT (Reuters) — BioNTech (NASDAQ:BNTX) has cut its 2023 revenue target by about 1 billion euros ($1.1 billion) on lower demand for the COVID-19 vaccine made with Pfizer (NYSE:PFE) but said the impact from write-downs at its U.S. partner was less then initially thought.

Investing.com — U.S. stocks are wobbling on Tuesday, ahead of the start of the latest two-day policy meeting of the Federal Reserve and as investors look toward Apple (NASDAQ:AAPL)'s earnings and the October jobs report.

Investing.com — Here is your Pro Recap of the biggest analyst cuts you may have missed today: downgrades at Cummins, JD.com, BioNTech, Crown Castle, and KB Home.

Check out the companies making headlines before the bell.

By Ludwig Burger

European shares climbed on Monday, with miners in the lead on optimism around demand from top consumer China, although trading was cautious as investors weighed prospects of an escalation in the Middle East conflict. The STOXX 600 was up 0.4% by 0707 GMT. The mining index rose 1.3% as prices of base metals were lifted by hopes of stronger demand from China after data last week signalled some signs of stabilisation in the world's second-largest economy. Also boosting the index was a nearly 4% gain in shares of SSAB after JP Morgan upgraded the Swedish steel company to «overweight» from «neutral». Global risk sentiment was still on shaky grounds over concerns that the Israel-Hamas conflict would spill over to the broader region, gaining steam after Iran warned Israel of escalation. Among other single stocks, Frankfurt-listed shares of BioNTech fell nearly 5% after partner Pfizer on Friday slashed its full-year revenue forecast on lower sales of its COVID-19 vaccine and treatment.

The Nobel Prize in Medicine has been awarded to two scientists whose work led to mRNA vaccines against COVID-19

U.S. regulators have approved updated COVID-19 vaccines from Pfizer and Moderna, shots aimed at revving up protection this fall and winter

(Reuters) — The U.S. drug regulator on Monday authorized updated COVID-19 vaccines from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) that closely match the widely circulating Omicron variants, allowing the deployment of the shots to start as soon as this week.

Joe Biden tested negative for the viral disease, according to a report published by The Associated Press. White House press secretary Karine Jean-Pierre said the president would continue testing regularly and be monitored for symptoms. Jill Biden will remain at the couple's home in Rehoboth Beach, Delaware, for the time being.

President Biden announced on Friday his intention to seek further funding from Congress to support the development of a new COVID-19 vaccine.

(Reuters) — Moderna (NASDAQ:MRNA) said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the «Eris» and «Fornax» subvariants in humans.

(Reuters) — Pfizer Inc (NYSE:PFE) said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the «Eris» subvariant in a study conducted on mice.

second Covid jab on the same arm as the first one or on the opposite arm could influence the body's immune response generated against the SARS-CoV-2 virus, new research from Germany says. Those who got jabbed on the same side, or ipsilaterally, generated more antibodies against the Covid-causing pathogen than those who got jabbed on the opposite side, or contralaterally, the study from Saarland University and other German institutes found. Further, median levels of infection-fighting CD8 T-cells generated in response to the spike-protein of the pathogen were found to be significantly lower in those contralaterally vaccinated. CD8 T-cells destroy virus-infected cells and render protection against severe disease. Consequently, after contralateral vaccination, fewer individuals (43 per cent) were found to have detectable levels of CD8 T-cells than after ipsilateral vaccination (67 per cent), the study published in the journal eBioMedicine said. Individual doses of two-dose vaccine-regimens are consecutively administered into the deltoid muscle, which is the large triangular muscle covering the shoulder joint. However, «little attention has so far been paid to the immunological effects of choosing the ipsilateral or the contralateral side for the second dose,» the authors wrote in the study.

In this article

In this article